Booth 3435
Cambridge, Massachusetts, United States
Established in 2014, XtalPi’s founders recognized a common hurdle in drug development in the space of solid polymorphism, which they successfully tackled with quantum physics predictions. Since then, XtalPi has maintained its focus on identifying and then attacking traditional bottlenecks in drug discovery by developing novel and disruptive technologies. Through considerable capital investments in automation and personnel, XtalPi now employs approximately 1000 individuals worldwide. Our expert team, located in our four geographic centers of excellence, has culminated in XtalPi successfully engaging in collaborative research with nearly all the top-20 pharmaceutical companies in the world.
Focus Areas